This is a preview of subscription content, log in via an institution to check access.
REFERENCES
M. Azria. The Calcitonins. Physiology and Pharmacology Karger, Basel, 1989.
G. Segre and P. Dal Pra. In A. Pecile (eds.), Calcitonin Excerpta Medica, Amsterdam, 1985, pp. 99–107.
M. Hanson, G. Gazdick, J. Cahill, and M. Augustine. In S. S. Davis, L. Illum, and E. Tomlinson (eds.), Delivery Systems for Peptide Drugs Plenum, New York, 1986, pp. 233–242.
K. C. Lee, E. E. Soltis, P. S. Newman, K. W. Burton, R. C. Mehta, and P. P. DeLuca. In vivo assessment of salmon calcitonin sustained release from biodegradable microspheres. J. Control. Release 17:199–206 (1991).
M. DeLuise, T. J. Martin, and R. A. Melick. Inactivation and degradation of porcine calcitonin by rat liver, and relative stability of salmon calcitonin. J. Endocrinol. 48:181–188 (1970).
F. E. Newsome, R. K. O'Dor, C. O. Parkes, and D. H. Copp. A study of the stability of calcitonin biological activity. Endocrinology 92:1102–1106 (1973).
S. B. Baylin, A. L. Bailey, T.-H. Hsu, and C. V. Foster. Degradation of human calcitonin in human plasma. Metabolism 26:1345–1354 (1977).
M. L. Heinitz, E. Flanigan, R. C. Orlowski, and F. E. Regnier. Correlation of calcitonin structure with chromatographic retention in high-performance liquid chromatography. J. Chromatogr. 443:229–245 (1988).
I. H. Lee, S. Pollack, S. H. Hsu, and J. R. Miksic. Influence of the mobile phase on salmon calcitonin analysis by reversedphase liquid chromatography. J. Chromatogr. Sci. 29:136–140 (1991).
M. C. Manning, K. Patel, and R. T. Borchardt. Stability of protein pharmaceuticals. Pharm. Res. 6:903–918 (1989).
V. B. Riniker, R. Neher, R. Maier, F. W. Kahnt, P. G. H. Byfield, T. V. Gudmundsson, L. Galante, and I. MacIntyre. Human calcitonin. I. Isolation and characterization. Helv. Chim. Acta. 51:1738–1742 (1968).
R. P. Diaugustine, B. W. Gibson, W. Aberth, M. Kelly, C. M. Ferrua, Y. Tomooka, C. F. Brown, and M. Walker. Evidence for isoaspartyl (deamidated) forms of mouse epidermal growth factor. Anal. Biochem. 165:420–429 (1987).
T. Geiger and S. Clarke. Deamidation, isomerization and racemization at asparaginyl and aspartyl residues in peptides. J. Biol. Chem. 262:785–794 (1987).
N. P. Bhatt, K. Patel, and R. T. Borchardt. Chemical pathways of peptide degradation. I. Deamidation of adrenocorticotropic hormone. Pharm. Res. 7:593–599 (1990).
K. Patel and R. T. Borchardt. Chemical pathways of peptide degradation. III. Effect of primary sequence on the pathways of deamidation of asparaginyl residues in hexapeptides. Pharm. Res. 7:787–793 (1990).
X. H. Zhou and A. Li Wan Po. Peptide and protein drugs. I. Therapeutic applications, absorption and parenteral administration. Int. J. Pharm. 75:97–115 (1991).
D. M. Johnson, R. A. Pritchard, W. F. Taylor, D. Conley, G. Zuniga, and K. G. McGreevy. Degradation of the LH-RH analog nafarelin acetate in aqueous solution. Int. J. Pharm. 31:125–129 (1986).
J. W. VanNispen. In D. D. Breimer and P. Speiser (eds.), Topics in Pharmaceutical Sciences 1987 Elsevier, Amsterdam, 1987, pp. 293–307.
V. J. Helm and B. W. Müller. Stability of gonadorelin and triptorelin in aqueous solution. Pharm. Res. 7:1253–1255 (1990).
V. J. Helm and B. W. Müller. Stability of the synthetic pentapeptide thymopentin in aqueous solution: Effect of pH and buffer on degradation. Int. J. Pharm. 70:29–34 (1991).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lee, K.C., Lee, Y.J., Song, H.M. et al. Degradation of Synthetic Salmon Calcitonin in Aqueous Solution. Pharm Res 9, 1521–1523 (1992). https://doi.org/10.1023/A:1015839719618
Issue Date:
DOI: https://doi.org/10.1023/A:1015839719618